GlassScriptPhysician profile
Dylan Gene Timmermann
NPI 1235838228
$18,968.21
in general payments reported to CMS, 2019-2025
22 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $698 · 2024: $3,856 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,600 · Food and Beverage: $6,061 · Consulting Fee: $2,443 · Travel and Lodging: $498 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,600.00 |
| Food and Beverage | $6,060.81 |
| Consulting Fee | $2,442.50 |
| Travel and Lodging | $498.28 |
| Education | $366.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $10,862.81 | 2024-2025 | Aklief, Dysport, Nemluvio |
| Incyte Corporation | $1,856.18 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $1,571.96 | 2024-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $1,425.52 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $949.28 | 2023-2025 | Sotyktu |
| Abbvie INC. | $458.72 | 2024-2025 | |
| Janssen Biotech, INC. | $382.23 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $310.98 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $214.37 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $183.81 | 2025 | |
| Lilly USA, LLC | $183.73 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $135.25 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $100.76 | 2025 | Dupixent |
| Amgen INC. | $77.14 | 2024-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $63.92 | 2025 | Klisyri, Seysara |
| Genzyme Corporation | $46.79 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.61 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.48 | 2025 | Cabtreo |
| Verrica Pharmaceuticals INC. | $15.33 | 2023 | Ycanth |
| Journey Medical Corporation | $15.11 | 2025 | |
| Organon LLC | $9.23 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Timmermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.